MicroRNAs as potential diagnostic biomarkers for bipolar disorder

Bridget Martinez1,2, Philip V Peplow3

  • 1Department of Pharmacology, University of Nevada-Reno, Reno, NV, USA.

PubMed

Insights

MicroRNAs show promise as biomarkers for bipolar disorder diagnosis and prognosis. Specific microRNAs in blood and plasma may help identify the condition and its clinical states.

Area of Science:

  • Neuroscience
  • Genetics
  • Biomarker Discovery

Background:

  • Abnormal microRNA expression is linked to brain development and disorders.
  • MicroRNAs are potential biomarkers for diagnosing and predicting bipolar disorder outcomes.

Purpose of the Study:

  • To review and identify microRNA biomarkers for bipolar disorder from recent human studies.
  • To assess microRNA expression changes related to treatment and clinical states in bipolar disorder.

Main Methods:

  • A PubMed search identified 18 original research articles on microRNA biomarkers in bipolar disorder (Jan 2011-June 2023).
  • Studies analyzed microRNA profiles in blood and brain tissues, including plasma, serum, and whole blood.
  • MicroRNA expression was correlated with treatment responses and clinical states (mania, depression, euthymia).

Main Results:

  • Several microRNAs (e.g., miR-140-3p, -30d-5p, -21-3p) were identified as potential biomarkers in whole blood, plasma, and serum.
  • Treatment with antipsychotics and other medications altered microRNA levels (e.g., miR-134, miR-219).
  • Specific microRNAs showed differential expression across manic, depressive, and euthymic states, and in distinguishing bipolar disorder from other psychiatric conditions.

Conclusions:

  • MicroRNAs hold significant potential as diagnostic and prognostic biomarkers for bipolar disorder.
  • Further research, including studies in adolescents and animal models, is needed to validate these findings and explore therapeutic interventions.